Next Article in Journal
Analysis of Tuberculosis Meningitis Pathogenesis, Diagnosis, and Treatment
Next Article in Special Issue
The PANDEMYC Score. An Easily Applicable and Interpretable Model for Predicting Mortality Associated With COVID-19
Previous Article in Journal
The Prognostic Model of Pre-Treatment Complete Blood Count (CBC) for Recurrence in Early Cervical Cancer
Previous Article in Special Issue
The Wide Spectrum of COVID-19 Clinical Presentation in Children
 
 
Article

Colchicine to Weather the Cytokine Storm in Hospitalized Patients with COVID-19

1
Robert Wood Johnson University Hospital Somerset, 110 Rehill Avenue, Somerville, NJ 08876, USA
2
Ernest Mario School of Pharmacy, 160 Frelinghuysen Road, Piscataway, NJ 08854, USA
3
Center of Excellence in Pharmaceutical Translational Research and Education, 160 Frelinghuysen Road, Piscataway, NJ 08854, USA
4
Department of Cell Biology and Neuroscience, Rutgers, The State University of New Jersey, Piscataway, NJ 08854, USA
5
IDCare, Hillsborough, NJ 08844, USA
6
Division of Pulmonary/Critical Care Medicine, Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ 08901, USA
7
Division of Rheumatology, Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ 08901, USA
*
Author to whom correspondence should be addressed.
Contributed equally to this manuscript.
J. Clin. Med. 2020, 9(9), 2961; https://doi.org/10.3390/jcm9092961
Received: 18 August 2020 / Revised: 8 September 2020 / Accepted: 9 September 2020 / Published: 14 September 2020
The repurposing of colchicine for the treatment of COVID-19 was suggested based in its immunomodulatory, anti-inflammatory, and anti-viral properties. We performed a single-center propensity score matched cohort study, including all consecutive COVID-19 patients admitted to a community hospital between 1 March 2020 and 30 May 2020. Patients were stratified according to the receipt of colchicine. The primary endpoint was defined as in-hospital death within 28-days follow-up. Secondary endpoints included favorable change in the Ordinal Scale for Clinical Improvement on days 14 and 28 versus baseline, proportion of patients not requiring supplemental oxygen on days 14 and 28, and proportion of patients discharged by day 28. In total data for 303 PCR positive COVID-19 patients were extracted and 66 patients were included in the 1:1 matched cohort study. At the end of the 28 day follow-up, patients receiving colchicine were approximately five times more likely to be discharged (odds ratio, 5.0; 95% confidence interval, 1.25–20.1; p = 0.023) and when comparing mortality, there were 3 deaths (9.1%) in patients receiving colchicine versus 11 deaths (33.3%) in the groups receiving standard of care (odds ratio, 0.20; 95% confidence interval, 0.05–0.80; p = 0.023). These observations warrant further investigation in large controlled clinical trials. View Full-Text
Keywords: colchicine; COVID-19; viral pneumonia; coronavirus; cytokine storm colchicine; COVID-19; viral pneumonia; coronavirus; cytokine storm
Show Figures

Figure 1

MDPI and ACS Style

Brunetti, L.; Diawara, O.; Tsai, A.; Firestein, B.L.; Nahass, R.G.; Poiani, G.; Schlesinger, N. Colchicine to Weather the Cytokine Storm in Hospitalized Patients with COVID-19. J. Clin. Med. 2020, 9, 2961. https://doi.org/10.3390/jcm9092961

AMA Style

Brunetti L, Diawara O, Tsai A, Firestein BL, Nahass RG, Poiani G, Schlesinger N. Colchicine to Weather the Cytokine Storm in Hospitalized Patients with COVID-19. Journal of Clinical Medicine. 2020; 9(9):2961. https://doi.org/10.3390/jcm9092961

Chicago/Turabian Style

Brunetti, Luigi, Oumou Diawara, Andrew Tsai, Bonnie L. Firestein, Ronald G. Nahass, George Poiani, and Naomi Schlesinger. 2020. "Colchicine to Weather the Cytokine Storm in Hospitalized Patients with COVID-19" Journal of Clinical Medicine 9, no. 9: 2961. https://doi.org/10.3390/jcm9092961

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop